Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
Precision BioSciences to Report First Quarter Results on May 13, 2024
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update